• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SenesTech Appoints Jack Karabees as Executive Vice President of Sales

    6/29/26 8:30:00 AM ET
    $SNES
    $TDOC
    Agricultural Chemicals
    Industrials
    Medical/Nursing Services
    Health Care
    Get the next $SNES alert in real time by email

    Veteran enterprise sales executive brings decades of experience scaling companies and leading successful commercial organizations

    SURPRISE, Ariz., June 29, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control solutions for managing rodent populations, today announced the appointment of Jack Karabees as Executive Vice President of Sales.

    SenesTech, Inc. is a pioneer in fertility control solutions for managing rodent populations. (PRNewsfoto/SenesTech, Inc.)

    Mr. Karabees brings more than three decades of experience building and leading professional B2B sales organizations and helping companies define the processes and systems necessary to achieve significant scale. In his new role, he will lead SenesTech's sales organization and be responsible for driving revenue growth, expanding market penetration and strengthening customer relationships across key channels.

    Most recently, Mr. Karabees served as Chief Revenue Officer of Intercept Telehealth, a provider of virtual critical care and telehealth services to health systems and hospitals. Prior to Intercept, he served as President and Executive Vice President of Sales at Consult A Doctor, helping guide the company from startup through its successful acquisition by Teladoc Health (NYSE:TDOC).

    Earlier in his career, Mr. Karabees served as Executive Vice President of Corporate Finance, Sales and Marketing for Entic, a cloud-based predictive analytics and optimization platform serving hospitals and large healthcare facilities. During his tenure, the company was acquired by Blackstone Group and subsequently sold to Aquicore. He also served as Senior Vice President of Sales at eLabor, a cloud-based workforce management and human resources software provider, helping lead the company through growth that resulted in separate divisional acquisitions by Microsoft Corporation and ADP.

    Mr. Karabees served as Executive Vice President of Investment Banking with Katalyst Securities and has been active in the entrepreneurial and investment community, serving as both a member and board member of New World Angels and Miami Innovation Fund. Throughout his career, companies and entrepreneurs have benefited from Mr. Karabees' operational expertise and his ability to build and scale professional B2B sales organizations. Mr. Karabees is a veteran of the United States Air Force and resides in Coral Gables, Florida, with his wife and two daughters.

    In addition, Mr. Karabees has been working closely with SenesTech in a consulting capacity, providing strategic guidance and supporting the Company's commercial initiatives. His appointment represents the next step in his involvement with the Company as SenesTech continues to build a professional sales organization and pursue its growth opportunities.

    "Jack has built and led successful professional B2B sales organizations throughout his career and has extensive experience helping companies define the processes and systems necessary to achieve significant scale," said Michael Edell, President and Chief Executive Officer of SenesTech. "Having worked with Jack for years at other companies and alongside him at SenesTech, I have seen firsthand what he is capable of building. We know there is a significant opportunity for our rodent birth control products not only in the direct-to-consumer market, but also across a number of B2B verticals, and we believe Jack's experience and leadership will help us capitalize on those opportunities and accelerate the Company's growth."

    Mr. Karabees added, "SenesTech has developed patented products, marketed under its Evolve and ContraPest brands, to address an immense problem in rodent population management, and I believe there is a tremendous opportunity for the Company across multiple markets. I am excited to join the team and look forward to building on the strong foundation already in place and helping the Company capitalize on the opportunities ahead."

    About SenesTech, Inc.

    SenesTech is the leader in rodent birth control solutions. The Company's patented products, marketed under its Evolve™ and ContraPest® brands, provide effective, sustainable approaches to long-term rodent population management that can be integrated into existing pest management programs or used independently. SenesTech serves both consumer and professional markets with science-based solutions aimed at addressing one of the world's most persistent pest challenges.

    For more information, visit https://senestech.com.  

    Safe Harbor Statement

    This press release contains forward-looking statements within the meaning of federal securities laws.  Such forward-looking statements include, among others, statements regarding the development of the Company's sales organization and growth opportunities, the potential opportunity for the Company's rodent birth control products in the direct-to-consumer market and across B2B verticals, and the new Executive Vice President of Sales' ability to help the Company capitalize on those opportunities and accelerate growth.You are cautioned that such statements are based on current expectations and assumptions and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the risk that the Company may not be successful in the commercialization of its products, or realize sufficient market acceptance of its products, or capitalize on market opportunities and accelerate growth; risks related to the Company's financial performance, including the ability to fund its ongoing operations; risks related to required regulatory approvals for and regulation of the Company's products; and other factors and risks identified from time to time in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, the Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    Investor Contact:

    Robert Blum, Lytham Partners, LLC

    (602) 889-9700, senestech@lythampartners.com

    Company Contact:

    Tom Chesterman, SenesTech, Inc.

    (928) 233-7533, investors@senestech.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-appoints-jack-karabees-as-executive-vice-president-of-sales-302812733.html

    SOURCE SenesTech, Inc.

    Get the next $SNES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNES
    $TDOC

    CompanyDatePrice TargetRatingAnalyst
    Teladoc Health Inc.
    $TDOC
    3/10/2026$11.00Hold → Buy
    Deutsche Bank
    Teladoc Health Inc.
    $TDOC
    2/26/2026$7.00Neutral → Buy
    BofA Securities
    Teladoc Health Inc.
    $TDOC
    12/9/2025$8.50Equal Weight
    Barclays
    Teladoc Health Inc.
    $TDOC
    11/13/2025$8.00Market Perform
    BMO Capital Markets
    Teladoc Health Inc.
    $TDOC
    7/25/2025$10.00Neutral
    Mizuho
    Teladoc Health Inc.
    $TDOC
    11/15/2024$14.00Buy
    Goldman
    Teladoc Health Inc.
    $TDOC
    9/17/2024$8.00 → $10.00Hold
    Jefferies
    Teladoc Health Inc.
    $TDOC
    2/29/2024$22.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SNES
    $TDOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Edell Michael bought $1,430 worth of shares (1,000 units at $1.43), increasing direct ownership by 25% to 5,000 units (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    7/8/26 5:01:03 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    President, U.S. Group Health Bliss Kelly sold $23,750 worth of shares (2,500 units at $9.50) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 84,878 units (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    7/6/26 4:05:27 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Chief Accounting Officer Catapano Joseph Ronald converted options into 2,083 shares and sold $5,942 worth of shares (653 units at $9.10), increasing direct ownership by 13% to 12,267 units (SEC Form 4) to satisfy withholding obligation

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    7/6/26 4:05:16 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $SNES
    $TDOC
    SEC Filings

    View All

    SEC Form 144 filed by Teladoc Health Inc.

    144 - Teladoc Health, Inc. (0001477449) (Subject)

    6/11/26 3:22:58 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    SenesTech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - SenesTech, Inc. (0001680378) (Filer)

    6/10/26 4:03:45 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form DEFA14A filed by SenesTech Inc.

    DEFA14A - SenesTech, Inc. (0001680378) (Filer)

    6/4/26 4:02:35 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    $TDOC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teladoc upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Teladoc from Hold to Buy and set a new price target of $11.00

    3/10/26 8:39:03 AM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Teladoc upgraded by BofA Securities with a new price target

    BofA Securities upgraded Teladoc from Neutral to Buy and set a new price target of $7.00

    2/26/26 12:11:08 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Teladoc with a new price target

    Barclays initiated coverage of Teladoc with a rating of Equal Weight and set a new price target of $8.50

    12/9/25 8:53:51 AM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $SNES
    $TDOC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teladoc Health to Announce Second Quarter 2026 Financial Results

    NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release second quarter 2026 results on Wednesday, July 29, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 833-461-5787 for U.S. participants and using the meeting ID # 478 236 923. For international participants, please visit the following link for global dial-in numbers, using the same meeting ID # 478 236 923: https://help.events.q4inc.com/eahc/international-dial-in-numbers. A live audio webca

    7/15/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    SenesTech's Evolve® Delivers Significant Reduction in Rodent Damage at Texas Agricultural Operation

    SURPRISE, Ariz., July 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control solutions for managing rodent populations, today announced successful results from the use of Evolve® Rat Birth Control™ at a 400-acre farming operation in Dalhart, Texas, where rodents had been causing persistent damage to underground irrigation infrastructure. The farm utilizes one of the world's leading irrigation systems for precision agriculture and sustainable water management. Prior to implementing Evolve, rodents routinely chewed through underground irrigation tape in search of water in the dry Texas climate, resul

    7/9/26 8:30:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

    NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee. Effective July 1, 2026, in connection with commencing employment as Head of Product of BetterHelp, David Packles was granted an award of restricted stock units covering 50,000 shares of Teladoc Health’s common stock, par value $0.001 per share ("Common Stock"). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The award was approved b

    7/3/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $SNES
    $TDOC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Edell Michael bought $1,430 worth of shares (1,000 units at $1.43), increasing direct ownership by 25% to 5,000 units (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    7/8/26 5:01:03 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $52,731 worth of shares (35,000 units at $1.51) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    7/2/26 8:00:15 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $39,102 worth of shares (25,416 units at $1.54) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    6/29/26 8:00:15 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    $TDOC
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Appoints Jack Karabees as Executive Vice President of Sales

    Veteran enterprise sales executive brings decades of experience scaling companies and leading successful commercial organizationsSURPRISE, Ariz., June 29, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control solutions for managing rodent populations, today announced the appointment of Jack Karabees as Executive Vice President of Sales. Mr. Karabees brings more than three decades of experience building and leading professional B2B sales organizations and helping companies define the processes and systems necessary to achieve significant scale. In his

    6/29/26 8:30:00 AM ET
    $SNES
    $TDOC
    Agricultural Chemicals
    Industrials
    Medical/Nursing Services
    Health Care

    SenesTech Appoints Michael Edell as President and Chief Executive Officer to Drive Revenue Growth and Scalable Sales Channels

    SURPRISE, Ariz., May 7, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a leader in humane pest control solutions, today announced the appointment of Michael Edell as President and Chief Executive Officer, effective May 6, 2026. The Company also announced Board leadership transition updates to support SenesTech's next phase of commercial growth and operational execution. Mr. Edell brings a proven track record of building and scaling consumer product businesses, with deep expertise in e-commerce, direct-to-consumer execution, and business

    5/7/26 8:30:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board's audit and compensation committees. "Susan brings a powerful combination of healthcare leadership and governance experience to the Board," said Kenneth H. Paulus, non‑

    3/30/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $SNES
    $TDOC
    Financials

    Live finance-specific insights

    View All

    Teladoc Health to Announce Second Quarter 2026 Financial Results

    NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release second quarter 2026 results on Wednesday, July 29, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 833-461-5787 for U.S. participants and using the meeting ID # 478 236 923. For international participants, please visit the following link for global dial-in numbers, using the same meeting ID # 478 236 923: https://help.events.q4inc.com/eahc/international-dial-in-numbers. A live audio webca

    7/15/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    SenesTech Reports Record Direct-to-Consumer and Subscription Growth Following Strategic E-Commerce Transition

    In-house e-commerce transition and new CEO expected to support scalable recurring revenue growth strategySURPRISE, Ariz., May 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced financial results for the first quarter ended March 31, 2026 and provided an update on the Company's acceleration of revenue under newly appointed Chief Executive Officer, Michael Edell. Q1 2026 Financial HighlightsRevenue increased 2% to $493,

    5/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, May 7, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products, will report financial results for its first quarter 2026, ended March 31, 2026, after the market close on Tuesday, May 12, 2026. The Company has scheduled a conference call that same day, Tuesday, May 12, 2026, at 5:00 pm ET, to review the results. First Quarter

    5/7/26 4:30:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    $TDOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by SenesTech Inc.

    SC 13G - SenesTech, Inc. (0001680378) (Subject)

    11/12/24 4:30:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials